{"nctId":"NCT00327444","briefTitle":"Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites","startDateStruct":{"date":"2006-07"},"conditions":["Ovarian Neoplasms","Ascites"],"count":58,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP速)"]},{"label":"Aflibercept","type":"EXPERIMENTAL","interventionNames":["Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP速)"]}],"interventions":[{"name":"aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP速)","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP速)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Participants who met the following criteria were eligible to participate in this study.\n\nInclusion Criteria:\n\n* Advanced ovarian epithelial cancer, treated with paracentesis\n* Platinum-resistant, and topotecan-resistant and/or liposomal doxorubicin-resistant disease;\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\< 2.\n\nExclusion Criteria:\n\n* Pseudomyxoma peritonei or peritoneal mesothelioma;\n* Transudative ascites;\n* Peritoneovenous or other shunt placed for malignant ascites management;\n* Recent (\\<6 months) cardiovascular event (pulmonary embolus, myocardial infarction, stroke) or gastrointestinal disease (ulcer, hepatic cirrhosis);\n* Known brain metastases;\n* Uncontrolled hypertension;\n* Recent treatment with chemotherapy, surgery or radiotherapy;\n* Prior treatment with VEGF or VEGFR inhibitor.\n\nThe above information is not intended to contain all considerations relevant to participation in a clinical trial.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Repeat Paracentesis (TRP)","description":"TRP was defined as the number of days between the date of randomization and the date of the first post-randomization paracentesis.\n\nFor participants who did not undergo a postrandomization paracentesis on study, TRP was calculated from randomization to the end of the double-blind treatment period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.3","spread":"7.70"},{"groupId":"OG001","value":"55.1","spread":"7.25"}]}]}]},{"type":"SECONDARY","title":"Area Under the Curve (AUC) for Participant Assessed Ascites Impact Measure (AIM)","description":"AIM 4 symptoms (abdominal discomfort, abdominal bloating, abdominal pain, and ability to move normally) are scored from 0 to 5, where higher scores represent worst outcomes. An AIM total score ranges from 0-20.\n\nA plot for (The AIM questionnaire total score - Baseline score) versus time were generated. AIM AUC represents the overall improvement (scored positive) if the area is below the baseline value or worsening (scored negative) if the area is above the baseline. AIM AUC for a participant is the sum of individual areas representing improvement (+) or worsening (-).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.8","spread":"148.07"},{"groupId":"OG001","value":"405.3","spread":"143.21"}]}]}]},{"type":"SECONDARY","title":"60-Day Frequency of Paracentesis (FOP)","description":"60-Day FOP was defined as the total number of paracenteses performed within the first 60 days after randomization during the double blind treatment period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":"0.69"},{"groupId":"OG001","value":"2.7","spread":"0.65"}]}]}]},{"type":"SECONDARY","title":"Plasma Levels of Free and VEGF-bound Aflibercept","description":"Free aflibercept and VEGF-bound aflibercept plasma concentrations were measured by separate enzyme-linked immunosorbent assay (ELISA). The limit of quantitation of free aflibercept was 15.6 ng/mL, and of VEGF-bound aflibercept was 43.9 ng/mL.\n\nPeak free aflibercept was estimated at the end of Cycle 1 (C1) administration. The median free and VEGF-bound trough concentrations were determined for each participant beyond Cycle 3 (C3), then mean values were estimated from these median values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.8","spread":"29.7"},{"groupId":"OG001","value":"62.1","spread":"29.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.33","spread":"3.67"},{"groupId":"OG001","value":"5.10","spread":"5.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.02","spread":"1.29"},{"groupId":"OG001","value":"3.49","spread":"1.48"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":25},"commonTop":["Vomiting","Fatigue","Oedema peripheral","Nausea","Diarrhoea"]}}}